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The increase of disease outbreaks caused by Vibrio spp. in aquatic organisms as well as 
in humans, together with the emergence of antibiotic resistance in Vibrio spp., has led to 
a growing interest in alternative disease control measures. Quorum sensing (QS) is a 
mechanism for regulating microbial gene expression in a cell-density dependent way. 
While there is good evidence for the involvement of auto-inducer 2 (AI-2) based 
interspecies QS in the control of virulence in multiple Vibrio spp., only few inhibitors of 
this system are known. From the screening of a small panel of nucleoside analogues for 
their ability to disturb AI-2 based QS, an adenosine derivative with a p-
methoxyphenylpropionamide moiety at C-3’, emerged as a promising hit. Its mechanism 
of inhibition was elucidated by measuring the effect on bioluminescence in a series of 
Vibrio harveyi AI-2 QS mutants. Our results indicate that this compound, as well as a 
truncated analogue lacking the adenine base, block AI-2 based QS without interfering 
with bacterial growth. The active compounds neither affected the bioluminescence 
system as such, nor the production of AI-2, but most likely interfered with the signal 
transduction pathway at the level of LuxPQ in V. harveyi. The most active nucleoside 
analogue (designated LMC-21) was found to reduce Vibrio spp. starvation response, to 
affect biofilm formation in Vibrio anguillarum, Vibrio vulnificus and Vibrio cholerae, to 
reduce pigment and protease production in V. anguillarum and to protect gnotobiotic 
Artemia from V. harveyi-induced mortality. 
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Vibrio species are ubiquitous in marine environments worldwide (Igbinosa & Okoh, 
2008). As opportunistic pathogens they can cause mild to severe infections in humans 
and marine animals. Vibriosis is one of the most prevalent fish diseases, mainly caused 
by Vibrio anguillarum, Vibrio alginolyticus, Vibrio parahaemolyticus, Vibrio harveyi, 
and Vibrio campbellii (Garcia et al., 1997; Austin & Zhang, 2006). Other Vibrio spp. are 
pathogenic for humans. Vibrio vulnificus is associated with gastro-intestinal infections 
primarily following the consumption of raw and undercooked seafood, but it can also 
cause wound or soft-tissue infections (Bross et al., 2007). In addition, systemic V. 
vulnificus infections are notorious for their high mortality rate (Chiang & Chuang, 2003). 
Vibrio cholerae is responsible for pandemic and epidemic outbreaks of cholera (Griffith 
et al., 2006). V. cholerae serotype O1 causes the majority of the outbreaks worldwide, 
while the O139 serotype has only been detected in South-East and East Asia (Sack et al., 
2004; Griffith et al., 2006). Cell-cell communication (quorum sensing, QS) in Vibrio spp. 
plays an important role in virulence. QS in Vibrio spp. involves three types of signal 
molecules. N-acyl-homoserine lactones (AHL) are used in the LuxM/N QS system, 
cholera auto-inducer 1 (CAI-1) in the CqsA/S and auto-inducer 2 (AI-2) in the LuxS/PQ 
QS system (Bassler et al., 1993; Bassler et al., 1997; Higgins et al., 2007; Ryan & Dow, 
2008). AI-2 is synthesized starting from S-adenosylmethionine, which (through a series 
of enzymatic reactions, including the reaction catalysed by LuxS) is converted to 4,5-
dihydroxy-2,3-pentanedione (DPD) (Surette et al., 1999; Winzer et al., 2002). The 
spontaneous cyclisation of DPD followed by esterification with a tetrahydroxyborate 
anion results in the formation of AI-2 (Miller et al., 2004). In Vibrio spp., sensing of 
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extracellular AI-2 involves two proteins, LuxP and LuxQ (Chen et al., 2002). At low AI-
2 concentration, LuxQ will be autophosphorylated resulting in the transfer of a phosphate 
group to LuxO via LuxU (Freeman & Bassler, 1999a; Freeman & Bassler, 1999b). 
Phosphorylation of LuxO leads to its activation and the production of small regulatory 
RNAs. These small RNAs, together with the chaperone protein Hfq, destabilise mRNA of 
the response regulator LuxR. In the absence of AI-2, LuxR is not produced and LuxR-
dependent genes are not transcribed. Binding of AI-2 to the LuxPQ complex initiates a 
switch from kinase to phosphatase activity, which results in the dephosphorylation of the 
downstream proteins LuxU and LuxO. Dephosphorylated LuxO is inactive and does not 
induce the production of small regulatory RNAs. Hence, the response regulator LuxR is 
produced and initiates transcription of target genes, including several virulence genes. 
Therefore, QS inhibitors are promising antipathogenic agents. Due to the presence of the 
luxS gene in diverse bacterial species, AI-2 is considered to be a signal for inter-species 
communication (Xavier & Bassler, 2003). However, the LuxPQ signal transduction 
system is restricted to Vibrionales (Sun et al., 2004; Rezzonico & Duffy, 2008). The 
increase of Vibrio disease outbreaks in aquatic organisms as well as in humans (Harvell 
et al., 2002; Boyd et al., 2008; Kapp, 2009), together with the emergence of antibiotic 
resistance in Vibrio spp. (Karunasagar et al., 1994; Scrascia et al., 2006), has resulted in a 
growing interest in alternative disease control measures (Lynch & Wiener-Kronish, 
2008). A novel approach consists of interfering with bacterial communication (Ni et al., 
2009). Several cinnamaldehyde and furanone derivatives disrupt AI-2 based QS in Vibrio 
spp. by decreasing the DNA-binding activity of the response regulator LuxR and are 
active both in vitro and in vivo (Defoirdt et al., 2006; Defoirdt et al., 2007; Brackman et 
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al., 2008). Other compounds, including S-anhydroribosyl-L-homocysteine and S-
homoribosyl-L-cysteine, block the production of AI-2 by inhibiting the key enzyme LuxS 
(Alfaro et al., 2004; Shen et al., 2006). Based on the concept of molecular mimicry and 
through virtual screenings using the crystal structure of LuxP, new AI-2 QS inhibitors 
have previously been discovered (Li et al., 2008; Ni et al., 2008a; Ni et al., 2008b). 
However, although these compounds affect bioluminescence in V. harveyi, they were 
neither evaluated for their effect on QS-regulated virulence factors, nor for their activity 
in vivo. The goal of the present study was to test whether previously described AI-2 QS 
inhibitors targeting LuxPQ and various compounds from our collection have the ability to 
block the production of QS-regulated virulence factors in Vibrio spp.  
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Bacterial strains and growth conditions 
All bacterial strains used in this study are listed in Table 1. They were cultured in Marine-
Broth (MB) (BD) in the presence of appropriate antibiotics at 30 °C with shaking, except 
for Escherichia coli DH5α and E. coli K12, which were grown in Luria-Bertani broth 
(LB) (BD) at 30 °C and 37 °C, respectively, without shaking.  
 
Compound library 
The compounds used in the present study consisted of a selected set of known AI-2 QS 
inhibitors, supplemented with a series of nucleoside (mainly: adenosine) analogues (Fig. 
1). 3’-Azido- (3’-N3-3’-dA) and 3’-amino-3’-deoxyadenosine (3’-NH2-3’-dA) have been 
prepared as reported (Azhayev & Smrt, 1978) and are nowadays also commercially 
available. For the synthesis of the amide analogues derived from 3’-NH2-3’-dA (i.e., 
LMC-23, LMC-20, IK-1, LMC-21, LMC-27 and LMC-28) we followed a procedure that 
was described before (Soenens et al., 1995). Briefly, the 3'-amino group of unprotected 
3’-NH2-3’-dA was acylated with the appropriate carboxylic acids using 
dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) and N-
hydroxysuccinimide (NHS) as coupling agents in a mixture of DMF and dichloromethane 
(Supplementary Data, Fig. S1). The synthetic route followed for the synthesis of the 3’-
branched-chain analogue SC-23, differing from LMC-21 by the insertion of a CH2 group 
between C-3’ of the ribofuranose ring and the amide moiety started from the previously 
described intermediate 1 (Kim et al., 2003) (Supplementary Data, Fig. S2). The 2-
modified adenosine analogues LMC-29, LMC-30 and LMC-35 were recently synthesized 
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and found to be potent adenosine A3 receptor antagonists/partial agonists (Cosyn et al., 
2006), while PVR-121 is an agonist for the same receptor (Ohno et al., 2004). The  
amides derived from 3-(4-methoxyphenyl)propanoic acid (i.e., SC-1, SC-2 and SC-3) 
were prepared by EDC-mediated coupling of the parent carboxylic acid with the 
appropriate amine in the presence of TEA. The synthesis of SC-20 started from the 
known sugar intermediate 4 (Supplementary Data, Fig. S3) that was converted to methyl 
glycoside 5 upon reaction with SnCl
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4 and dry MeOH (Moradei et al., 1991). Remarkably, 
during this reaction a larger amount of 6 was formed. The reaction mixture could be 
efficiently separated by flash chromatography and 5 and 6 were separately deprotected 
upon treatment with NH3 in MeOH, thereby affording 7.1 and 7.2. NMR-analysis 
revealed that 7.1 and 7.2 only differ at the anomeric position (α- or β-MeO group). 
Although the configuration of each anomer remains uncertain, we anticipate that 7.1 
represents the β-anomer, since it was formed from 5, which still possessed the 
participating acetate group at C-2. Subsequently, we continued with azide 7.2 
(presumably the α-anomer), which was reduced through a Staudinger reduction. Finally, 
the resulting amine was coupled to 3-(4-methoxyphenyl)propanoic acid using HCTU as 
the coupling agent. All synthesized compounds were structurally confirmed using 1H- 
and 13C nuclear magnetic resonance spectroscopy and exact mass measurements 
(Supplementary Data) and were shown to possess a purity of at least 95% by combustion 
analysis. The previously described AI-2 QS inhibitor, 2-(2-
thienylsulfonyl)ethanethioamide (KM-03009) (Li et al., 2008) was purchased from Acros 
Organics, while pyrogallol (Ni et al., 2008a) and 4-methoxycarbonyl-phenylboronic acid 
(MCPBA) (Ni et al., 2008b) were purchased from Sigma-Aldrich. If necessary, 
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compounds were diluted in DMSO (final concentration of 0.5 % v/v). The stock solutions 
were stored at -20 °C. Control solutions contained the same amount of DMSO. 
 
Determination of the minimal inhibitory concentrations (MIC) 
MICs were determined for each compound by using a microdilution assay, as previously 
described (Brackman et al., 2009). MB and LB medium were used for all Vibrio spp. and 
both E. coli strains, respectively. The plates were incubated and the absorption at 590 nm 
was measured after 24 h using a Victor Wallac² multilabel counter (Perkin Elmer Life 
and Analytical Sciences).  
 
Identification of the molecular target of the QS inhibitors 
The assay for the effect on constitutively expressed bioluminescence (using E. coli DH5α 
containing the pBlueLux plasmid), the bioassay for LuxS inhibition (using V. harveyi 
MM30) and assays to determine the molecular target of the compounds tested (using V. 
harveyi BB120, BB170, BB886, JAF375, JAF553, JAF483, JMH597 and BNL258) were 
conducted as described previously (Brackman et al., 2008). Each compound was tested at 
least six times in triplicate (n ≥ 18). 
 
Effect on QS regulated virulence phenotypes in vitro  
The effect of AI-2 QS inhibitors on pigment production and protease activity in V. 
anguillarum LMG 4411 was determined as described previously (Croxatto et al., 2002). 
Each compound was tested at least twice in triplicate (n ≥ 6). Biofilms were grown 
according to Brackman et al. (2008). In brief, the Vibrio strains were grown overnight in 
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MB and approximately 108 colony forming units ml-1 was added to the wells of a 96 well 
microtiter plate in the presence or absence of QSI compounds. Bacteria were allowed to 
adhere and grow without agitation for 4 h at 30°C. After 4 h, plates were emptied and 
rinsed with sterile physiological saline (PS). After this rinsing step, fresh MB (with or 
without compounds) was added and the plate was incubated for 20 h at 30°C. 
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Biofilm biomass was quantified by crystal violet (CV) staining (Peeters et al., 2008). The 
control signal corresponds to an A590 of 0.604 ± 0.108 and 0.639 ± 0.129 for V. 
anguillarum LMG4411 and V. vulnificus LMG16867, respectively. For quantification of 
the number of metabolically active (i.e. living) cells in the biofilm, a resazurin assay was 
used (Peeters et al., 2008). Each compound was tested at least six times in triplicate (n ≥ 
18). 
 
Effect on QS regulated stress responses in vitro 
Vibrio spp. were grown overnight in MB, cells were collected by centrifugation and 
resuspendend in artificial seawater (ASW) (Bang et al., 2007). 1 ml of the bacterial 
suspension was transferred to 100 ml glass bottles containing 19 ml ASW (with and 
without test compound). These suspensions were incubated at 30 °C without shaking. 
After 48 h, 1 ml samples were taken and the number of culturable cells was determined 
by plating serial dilutions on TSA (Oxoid) plates containing 2 % (w/v) NaCl. Results 
were expressed as numbers of viable cells present after 48 h. Each assay was repeated at 
least three times. The effect of the compounds on susceptibility of all the Vibrio strains 
tested towards doxycycline and chloramphenicol was determined as described previously 
(Brackman et al., 2008). Each assay was repeated at least three times. A change in MIC 
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was considered relevant in case of a shift of more than two doubling dilutions in either 
direction. 
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Artemia challenge tests  
All experiments were performed with high quality hatching cysts of Artemia franciscana 
(EG Type, batch 6940, INVE Aquaculture). 200 mg of cysts were hydrated in 18 ml of 
tap water during 1 h. The procedure of Marques et al. (2004) was used to obtain sterile 
decapsulated cysts and nauplii. Challenge tests (in triplicate) were performed as described 
previously (Brackman et al., 2008).  
 
Cytostatic activity assay 
The murine (L1210) and human (CEM, HeLa) cells were seeded in a concentration of 
5.0-7.5 x 104 cells per 200 µl in wells of a 96-well microtiter plate in the presence of 
serial (5-fold) dilutions of the test compound, using RPMI-1640 culture medium 
supplemented with 2 mM L-glutamine, 0.075 % (w/v) NaHCO3, and 10 % (w/v) foetal 
bovine serum. After 48 h (L1210) or 72 h (CEM, HeLa), the cell numbers were 
determined using a Coulter Counter (Analis). The IC50 or 50 % inhibitory concentration 
of the compound represents the concentration required to inhibit cell proliferation by at 
least 50 %. 
 
Statistics  
The normal distribution of the data was checked using the Shapiro–Wilk test. Normally 216 
and non-normally distributed data were analyzed using an independent samples T-test and 217 
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the Mann–Whitney U test, respectively. Statistics were performed using SPSS software, 218 
version 17.0. 219 
220 
221 
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Inhibition of AI-2 controlled bioluminescence  
The antimicrobial activity of all compounds was evaluated against all strains used in the 
present study and MICs were found to be higher than 320 µM (160 µM for pyrogallol). 
Unless otherwise mentioned, the compounds were used in a concentration of 40 µM, 
which is well-below the MIC for all strains tested. Bioluminescence in a constitutively 
bioluminescent strain E. coli DH5αpBluelux was not inhibited by any of the compounds 
tested (Supplementary Data, Table S1). The effect on AI-2 QS was assessed using V. 
harveyi BB170. LMC-21 was the most active adenosine derivative and a concentration-
dependent inhibitory effect was observed (Fig. 2). Its isomer LMC-28, which only 
differed in the substitution site of the methoxy group, and SC-20, a truncated 
ribofuranosyl analogue, also inhibited AI-2 QS (Fig. 2), but proved significantly weaker 
compared to LMC-21. SC-23 yielded in a significant inhibition of QS in the V. harveyi 
BB170 reporter strain only when tested in a concentration above 40 µM (Fig. 2). In 
addition, MCPBA, KM-03009 and pyrogallol were also able to block the AI-2 QS system 
(Fig. 2). All the other compounds did not result in a reduction in bioluminescence, even 
when used in higher concentrations (up to 160 µM). 
 
Molecular target of the phenylpropionamidofuranosyl derivatives 
To identify the molecular target of the 3’-deoxy-3’-(4-
methoxyphenylpropionamido)ribofuranosyl derivatives, bioluminescence assays were 
conducted using several AI-2 QS mutants. No inhibitory effects were observed using the 
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V. harveyi JAF375 and V. harveyi BB886 mutant, while inhibitions were observed using 
the V. harveyi JMH597 mutant, suggesting an effect on AI-2 QS. The supernatants of 
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Escherichia coli K12 treated with the compounds revealed no difference in AI-2 activity 
compared to the control. Further, LMC-21 blocked bioluminescence in V. harveyi MM30, 
but not in V. harveyi JAF553, JAF483 or BNL258, suggesting that the target is located 
upstream of the mutations in the AI-2 signal transduction pathway and most-likely is the 
LuxPQ complex in V. harveyi. Similar results were obtained with SC-23, LMC-28, 
MCPBA and KM03009, suggesting that these molecules also target LuxPQ. 
 
Effect on protease activity and pigment production 
LMC-21 significantly decreased pigment production by V. anguillarum LMG4411 after 
48 h of growth but none of the other compounds tested was able to significantly alter 
pigment production (Table 2). Addition of LMC-21, MCPBA or pyrogallol resulted in a 
significantly decreased V. anguillarum LMG4411 protease activity (Table 2). 
 
Effect on in vitro grown biofilms 
The effect of the AI-2 QS inhibitors on the number of metabolically active cells in the 
biofilms of several Vibrio strains was evaluated using a rezasurin assay. This assay 
revealed no significant decrease in the number of metabolically active cells in the 
biofilms of the different Vibrio strains following treatment (Supplementary Data, Table 
S2). In contrast, several compounds decreased the crystal violet (CV) staining of V. 
anguillarum LMG 4411 and V. vulnificus LMG16867 biofilms (Table 2). However, no 
significant anti-biofilm effects were observed for V. harveyi BB120 and V. campbellii 
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LMG21363. In addition, the use of LMC-21 yielded in a minor but significant increase in 
CV signal for V. cholerae El Tor NCTC8457 (15 ± 8 % compared to the untreated 
control).  
 
Effect on susceptibility of Vibrio spp. to stress 
The effect of the different compounds on the starvation response and on the antimicrobial 
susceptibility of the different Vibrio spp. was investigated. Upon treatment with LMC-21, 
cell numbers significantly decreased in all Vibrio spp. (Table 3). Treatment with 
MCPBA, pyrogallol and KM-03009 reduced the number of culturable cells in some 
Vibrio spp. only (Table 3). There were no significant differences in the MIC’s of all 
Vibrio strains tested for chloramphenicol and doxycycline when used alone or in 
combination with a QS inhibitor (Supplementary Data, Tables S3 and S4). 
 
Effect on virulence in vivo and cytotoxicity  
High mortality rates were observed when exposing Artemia to V. harveyi BB120, but 
LMC-21 was able to completely protect Artemia during bacterial challenge (Fig. 3). 
LMC-21 alone had neither an effect on Artemia shrimp (Fig. 3) nor on V. harveyi BB120 
(data not shown). In addition LMC-21 was found to have IC50 values being ≥ 250 µM 
(L1210 cells) or ≥ 125 µM (CEM and HeLa cells). 
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QS is an important regulator of bacterial virulence in some bacterial species. 
Accordingly, QS inhibition is gaining interest as a potential alternative strategy for the 
treatment of bacterial infections. Although LuxS appears to be omnipresent in the 
bacterial world, the LuxPQ signal transduction system is restricted to Vibrionales (Sun et 
al., 2004; Rezzonico & Duffy, 2008). This makes the AI-2 receptor complex of 
Vibrionales an interesting target for the selective control of Vibrio spp. QS-regulated 
virulence. 
In this study, we not only confirmed the QS inhibitory activity of several established AI-2 
QS inhibitors, but we also discovered several new inhibitors. To identify their molecular 
target, we evaluated the effect of the most active compound (LMC-21) on different V. 
harveyi QS mutants. Although we originally anticipated that certain adenosine analogues 
might disturb the biosynthesis of DPD, due to their structural similarity with S-
adenosylmethionine, our data indicate that LMC-21 exerts its effect at the level of the AI-
2 transduction system rather than at that of AI-2 production. For these experiments, 
several V. harveyi QS mutants with mutations in the AI-2 signal transduction system 
were used. V. harveyi JAF553 and JAF483 contain a point mutation in the luxU and luxO 
genes, respectively, thereby preventing phosphorelay capacity of LuxU and LuxO. V. 
harveyi BNL258 has a Tn5 insertion in the hfq gene, resulting in a non-functional Hfq 
protein. Since V. harveyi strains JAF553, JAF483 and BNL258 are all constitutively 
luminescent, a lack of inhibition of bioluminescence in one of these indicates that the 
inhibitor acts upstream of the mutated protein. Our compound proved incapable of 
blocking bioluminescence in these three QS mutants. This suggests that the target of the 
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3-(methoxyphenylpropionamido)ribofuranosyl derivatives is the upstream component of 
the AI-2 signalling transduction pathway, LuxPQ. In addition, no effect was observed 
when testing the compound in V. harveyi BB886, a mutant which lacks the LuxP receptor 
required for AI-2 response and in V. harveyi JAF375, a mutant which lacks LuxQ. 
Although several compounds inhibit the AI-2 QS system, there are few reports on QS 
inhibitors targeting LuxPQ. Phenylboronic acids, pyrogallol derivatives and 2-(2-
thienylsulfonyl)ethanethioamide, previously reported to block the AI-2 QS system at the 
level of LuxPQ (Li et al., 2008; Ni et al., 2008a; Ni et al., 2008b), were at best as active 
as LMC-21. None of these compounds has been previously evaluated for its effect on AI-
2 related virulence. One molecule from each group of LuxPQ inhibitors was selected for 
further experiments. LMC-21 was not only able to reduce pigment production in V. 
anguillarum LMG4411, but also decreased protease activity in this strain. In contrast, 
none of the established QS inhibitors targeting LuxPQ were able to block pigment 
production or to reduce protease more than did LMC-21. In addition, LMC-21 decreased 
the biofilm biomass of V. anguillarum and V. vulnificus, without reducing the number of 
viable cells present in the biofilms. Pyrogallol only decreased biofilm biomass in V. 
vulnificus, but to a higher extent than LMC-21. These data confirm the finding that 
pigment and protease production in V. anguillarum and biofilm formation in V. 
anguillarum, V. vulnificus and V. cholerae are (at least partially) controlled by the AI-2 
QS system (Croxatto et al., 2002; Zhu et al., 2002; Hammer & Bassler, 2003; Lee et al., 
2007; Brackman et al., 2008). Mutations in the LuxR homologs of V. anguillarum 
(VanT) and V. vulnificus (SmcR) were shown to reduce biofilm formation in these 
species indicating that AI-2 QS may promote biofilm formation in these species 
 16
(Croxatto et al., 2002; Lee et al., 2007). In contrast, V. cholerae HapR represses the 
expression of vps genes (involved in the production of exopolysaccharides) and biofilm 
formation (Zhu et al., 2002; Hammer & Bassler, 2003) indicating that AI-2 QS 
negatively influences biofilm formation in this species. However, the main QS-signalling 
molecule in V. cholerae is CAI-1 and this may explain the limited impact of AI-2 QS 
inhibitors on V. cholerae biofilm formation. Whether the increase in V. cholerae biomass, 
due to LMC-21, would impose problems in in vivo situations remains to be determined. 
In addition, Vibrio spp. are also known to regulate stress adaptation by means of their QS 
system. AI-2 is capable of regulating different stress responses, including starvation in V. 
cholerae, V. vulnificus, V. anguillarum and V. angustum (McDougald et al., 2001; 
McDougald et al., 2003; Larsen et al., 2004; Joelsson et al., 2007; Lee et al., 2007; 
Weber et al., 2008). Our data indicate that LMC-21 suppresses the QS-regulated 
starvation response in all Vibrio spp. used, while the other compounds increased 
susceptibility to starvation-associated stress conditions in some Vibrio spp. only and that 
to a lesser extent than LMC-21. However, our results indicate that AI-2 inhibition in five 
Vibrio spp. did not change their antimicrobial susceptibility. Of all the compounds tested, 
LMC-21 was the most interesting one since it was clearly at least as active in inhibiting in 
vitro virulence compared to the other active compounds tested in this study. Although a 
decrease of virulence in vitro is not always linked to a decrease of virulence in vivo, 
LMC-21 was shown to be a potent suppressor of V. harveyi BB120 virulence in vivo. 
LMC-21 had no effect on Artemia survival as such and its lack of cytotoxicity, when used 
at 40 µM, was confirmed using murine and human cell lines. It is interesting to notice 
that halogenated furanones, well-documented QS inhibitors, have toxic side-effects in 
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concentrations comparable to those used in the present study (Defoirdt et al., 2006; 
Janssens et al., 2008).  
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In a preliminary search for the active pharmacophore of LMC-21, we synthesized a 
couple of compounds based on the phenylpropionamidofuranosyl backbone. Based on 
their effect on AI-2 regulated bioluminescence in V. harveyi BB120, we identified the 
most important structural elements required for achieving QS inhibition. Minor changes, 
e.g. removing the methoxy group from para (LMC-21) to meta position (LMC-28) or the 
insertion of an extra CH2 group between the phenylpropionamido substituent and the 
ribose moiety (SC-23) resulted in a decreased activity. Other molecules strongly 
resembling LMC-21, e.g. LMC-20 (longer side chain), LMC-23 (lacking the methoxy 
substituted aromatic ring), LMC-27 (lacking the methoxy substitution on the aromatic 
ring) and IK-1, failed to inhibit the AI-2 QS system and all together point toward a 
specific (receptor mediated) effect. We also investigated the importance of the adenine 
moiety present in LMC-21 by evaluating the effect of SC-1, SC-2, SC-3 and SC-20. Only 
SC-20 inhibited AI-2 QS, clearly showing that the ribofuranose moiety is required for 
activity. In addition, these results show that, although an adenine group is not essential 
for activity, its presence results in more active compounds. However, the molecular 
interaction of these compounds with LuxPQ remains to be determined. 
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Table 1: Strains used in this study. BCCM/LMG: Belgian Co-ordinated Collections of 
Micro-organisms/Laboratory of Microbiology collection (Ghent University, Belgium); 
HPACC: Health Protection Agency Culture collection. 
Strain Additional information Reference or source 
Vibrio harveyi    
BB120 Wild type from which strains 
BB170, BB886, MM30, JAF553, 
JAF483, BNL258, JAF375 and 
JMH597 are derived 
[Bassler et al., 1997] 
BB170 luxN::Tn5 [Bassler et al., 1993] 
BB886 luxPQ::Tn5 KanR 
 
 
 
 
[Bassler et al., 1994] 
MM30 luxS::Tn5 [Surette et al., 1999] 
JAF553 luxU H58A linked to KanR [Freeman & Bassler, 1999a] 
JAF483 luxO D47A linked to KanR [Freeman & Bassler, 1999b] 
BNL258 hfq::Tn5lacZ [Lenz et al., 2004] 
JAF375 luxN::CmR luxQ::KanR [Freeman & Bassler, 1999b] 
JMH597 luxN::Tn5 cqsS::CmR [Defoirdt et al., 2006] 
Vibrio anguillarum   
LMG 4411 Isolated from young sea trout 
(Salmo trutta) 
BCCM/LMG 
Vibrio campbellii   
LMG 21363 Isolated from Penaeus monodon 
juvenile, lymphoid organ 
BCCM/LMG 
Vibrio cholerae   
NCTC8457 Isolated from human, biotype El 
Tor 
HPACC 
Vibrio vulnificus   
LMG 16867 Isolated from tank water on eel BCCM/LMG 
 30
 31
farm 
Escherichia coli    
DH5αpBlueLux Strain (not producing AI-2) 
containing  pBluelux polylinker 
and luxCDABE genes 
[Brackman et al., 2008] 
K12  AI-2 producing strain [Ren et al., 2004] 
Table 2: Effect of the AI-2 QS inhibitors (40 µM) on QS-regulated phenotypes. *: significantly different compared to an untreated 
control (p < 0.05; independent samples T-test). 
629 
630 
   
Compound 
Protease activity† Pigment production‡ Biofilm formation§
V. anguillarum V. anguillarum V. anguillarum V. vulnificus 
LMG4411 LMG4411 LMG4411 LMG16867 
LMC-21 23 ± 3 %* 19 ± 10 %* 35 ± 11 %* 17 ± 15 %* 
KM-03009 5 ± 12 % 2 ± 13 % 2 ± 22 % 5 ± 24 % 
MCPBA 20 ± 2 %* 5 ± 16 % 36 ± 8 %* 18 ± 16 %* 
 
Pyrogallol 18 ± 5 %* 10 ± 22 % 10 ± 10 % 40 ± 9%* 
631 
632 
633 
634 
635 
636 
 
† % reduction in protease activity compared to an untreated control (A590 of 1.230 ± 0.132) (± SD)  
‡ % reduction in pigment production compared to an untreated control (A405 of 0.480 ± 0.090)(± SD) 
§% reduction in biofilm biomass (crystal violet staining) compared to an untreated control (± SD) 
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Table 3: Effect of the AI-2 QS inhibitors (40 µM) on QS regulated starvation response. Data are presented as numbers of viable cells 
(x108) present after 48 h. *: significantly different from number of cells present after 48 h in the control (p < 0.05; Mann-Whitney U) 
 
Compounds Number of viable cells (x108) (± SD) 
 V. anguillarum V. campbellii V. cholerae V. harveyi V. vulnificus 
 LMG4411 LMG21363 NCTC8457 BB120 LMG16867 
Initial number of cells 1.05 ± 0.30 1.00 ± 0.23 1.16 ± 0.11 1.15 ± 0.14 1.11 ± 0.21 
Control 0.77 ± 0.25 0.91 ± 0.18 1.10 ± 0.07 1.19 ± 0.45 1.09 ± 0.21 
LMC-21  0.08 ± 0.07* 0.47 ± 0.09* 0.86 ± 0.12*  0.53 ± 0.43* 0.67 ± 0.01* 
KM-03009 0.58 ± 0.07 0.93 ± 0.46 0.94 ± 0.45 0.85 ± 0.16* 1.11 ± 0.17 
MCPBA  0.32 ± 0.17* 1.02 ± 0.32 1.24 ± 0.66 1.17 ±0.37 0.93 ± 0.11 
Pyrogallol 0.21 ± 0.04* 0.56 ± 0.15* 0.91 ± 0.13 1.22 ± 0.67 1.03 ± 0.05 
 640 
Fig. 1: Overview of all analogues used in this study and previously not investigated in the 
context of QS or biofilm inhibitory activity (A, B and C) and compounds previously only 
investigated for their effect on AI-2 QS (D). 
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Fig. 2: Bioluminescence in V. harveyi BB170 in the absence (control) and presence of QS inhibitors. Bioluminescence measurements 
were performed 6 h after the addition of the compounds. Bioluminescence of the control (without addition of compound) was set at 
100 % and the responses for other samples were normalised accordingly. The error bars represent the standard deviation. 
Bioluminesence was significantly lower than the untreated control for all compounds (p < 0.05). 
652 
653 
654 
655 
656  
 36
 37
657 
Fig. 3: Effect of LMC-21 on the survival of Artemia. Control: survival of Artemia without challenge with V. harveyi BB120 and 
without LMC-21. Control + LMC-21: survival of 
658 
659 
660 
661 
662 
663 
Artemia without challenge with V. harveyi BB120 in the presence of LMC-21 (40 
µM). V. harveyi BB120: survival of Artemia after challenge with V. harveyi BB120 in the absence of LMC-21. V. harveyi BB120 + 
LMC-21: survival of Artemia after challenge with V. harveyi BB120 and treatment with LMC-21 (40 µM). *: Survival significantly 
different from the treatment with pathogen alone (p < 0.001). 
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AI-2 quorum sensing inhibitors affect the starvation response and reduce 
virulence in several Vibrio species, most likely by interfering with LuxPQ  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
 
Gilles Brackman, Shari Celen, Kartik Baruah, Peter Bossier, Serge Van 
Calenbergh, Hans J Nelis, Tom Coenye 
 
 
Supplementary material including:  
 
Figure S1 : Synthesis of the amide analogues derived from 3’-NH2-3’-dA 
 
Figure S2 : Synthetic route followed for the synthesis of the 3’-branched-chain analogue SC-
23 
 
Figure S3 : Synthesis of SC-20 
 
Supplementary methods : Synthesis procedures, 1H- and 13C nuclear magnetic resonance 
spectroscopy and exact mass measurements of compounds synthesised during the present 
study 
 
Supplementary Table 1: Lack of effect of various compounds on the constitutive 
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Figure S1 : Synthesis of the amide analogues derived from 3’-NH2-3’-dA 
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a) NHS, DCC or DIC, RCOOH, DMF/CH2Cl2, rt, 5 days 
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Figure S2 : Synthetic route followed for the synthesis of the 3’-branched-chain analogue SC-
23 
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a) NH3 in EtOH (2 M), 105 °C, 45 h, NH3 in MeOH (7 M), rt, 16 h, then: NaOMe, MeOH, rt, 
20h; b) PPh3, THF, pyridine, rt, 8 h, then H2O, rt, 16 h; c) [3-(4-methoxyphenyl)propanoic 
acid, HCTU, dipea, DMF, rt, 1 h], DMF, rt, 18 h; *yield over 2 steps. 
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Figure S3 : Synthesis of SC-20 54 
55  
O
TolO
N3
OAc
OAc
O
TolO
N3
OMe
OAc
O
TolO
N3
OMe
OH
6; 52 %
5; 8 %
O
HO
N3
OMe
OH
O
HO
N3
OMe
OH
a
b
b4
7.1
7.2
93 %
quant.
 
 
O
HO
N3
OMe
OH
O
HO
H2N
OMe
OH
O
HO
NH
OMe
OH
O
Oc d
7.2 8 S
33 %*
C-20
56 
57 
58 
59 
60 
61 
62 
a) SnCl4, DCM, 0 °C, 15 min, MeOH, 0 °C, 1 h, 0 °C → rt, 3 h; b) NH3 in MeOH (7 N), rt, 43 
h; c) PPh3, pyridine, rt, 8 h, H2O, rt, 16 h; d) [3-(4-methoxyphenyl)propanoic acid, HCTU, 
dipea, DMF, rt, 1 h], DMF, rt, 23 h; * yield over 2 steps. 
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Supplementary methods : Synthesis procedures, 1H- and 13C nuclear magnetic resonance 
spectroscopy and exact mass measurements of compounds synthesised during the present 
study 
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1. Synthesis of 3’-deoxy-3’-amidoadenosines (LMC-23, LMC-20, IK-1, LMC-21, LMC-
27, LMC-28), exemplified for LMC-21 
To a solution of 3’-NH2-3’-dA (11.32 mg; 42.5 µmol) in DCM (1.2 mL) and DMF 
(0.5 mL), NHS (6.97 mg; 60.6 µmol) and DIC (0.01 mL; 64.2 µmol) were added. After 
stirring for 45 min at rt under N2-atmosphere, TLC (DCM/0.6 N NH3 in MeOH 4:1) indicated 
the reaction to be incomplete. To increase the solubility of the starting material the DCM was 
largely evaporated and DMF (0.5 mL) was added, followed by an additional amount of DIC 
(0.01 mL). After 5 days the starting amine was completely converted. The solvents were 
evaporated and the residue purified by column chromatography (DCM/0.6 N NH3 in MeOH 
93:7) to afford the title compound as a light yellow oil (10.16 mg; 56 %). 
1H-NMR (300 MHz, C5D5N − d5): δ 8.99 (s, 1H, arom. H); 8.72 (br.s, 1H, -CO-NH-); 
8.63 (s, 1H, arom. H); 8.55 (br.s, 1H, -OH); 8.32 (br.s, 2H, -NH2); 7.23 (d, J = 8.7 Hz, 2H, 
arom. H); 6.92 (d, J = 8.7 Hz, 2H, arom. H); 6.67 (d, J = 2.3 Hz, 1 H, H-1’); 5.55 – 5.45 (m, 
1H, H-3’); 5.21 (dd, J = 2.2 and 5.4 Hz, 1H, H-2’); 5.02 (br.s, 1H, -OH); 4.66 (dt, J = 2.4 and 
7.9 Hz, 1H, H-4’); 4.37 (dd, J = 2.1 and 12.3 Hz, 1H, H-5’A); 4.21 (dd, J = 3.2 and 12.6 Hz, 
1H, H-5’B); 3.63 (s, 3H, CH3-O-); 3.22 − 3.00 (m, 2H, -CH2-CO-NH-); 2.90 − 2.72 (m, 2H, -
Ph-CH2-); 13C-NMR (75 MHz, C5D5N − d5): δ 173.83; 159.14; 158.12; 154.08; 140.05; 
134.45; 130.39; 121.66; 114.91; 92.23; 85.65; 75. 61; 62.39; 55.70; 52.07; 39.01; 31.88; 
HRMS (ESI-MS): m/z: calcd: 429.1881 [M+1]; found 429.1891 [M+1]. 
 
 
2. Synthesis of 3’-deoxy-3’-C-(3-(4-methoxyphenyl)propionamidomethyl)adenosine (SC-
23) 
 
2.1. Synthesis of 9-(3-C-azidomethyl-3-deoxy-β-D-ribofuranosyl)adenine (2) 
1 (398.67 mg; 0.82 mmol), dissolved in a 2 M solution of NH3 in EtOH (5 mL), was 
stirred for 22 h in a sealed tube at 105 °C. After that time TLC (EtOAc) indicated the 
incomplete deprotection of 1. Addition of an extra amount of NH3 in EtOH (2 M, 5 mL) and 
NH3 in MeOH (7 N, 5 mL) didn’t solve this issue. After evaporation of the reaction mixture, a 
solution of NaOMe (30%)  in MeOH (20 mL) was added. After stirring for 16h at rt, an 
additional amount of the ethanolic NaOMe solution (20 mL) was added and the reaction 
temperature was raised to 40 °C. After stirring for an additional 4h, the reaction was quenched 
by addition of H2O. The title compound was obtained as a white solid (200.44 mg; 0.65 
mmol; 80%) after purification by column chromatography (DCM/MeOH 9:1). 
1H-NMR (300 MHz, (CD3)2SO – d6): δ 8.41 (s, 1H, arom. H); 8.15 (s, 1H, arom. H); 
7.29 (s, 2H, -NH2); 6.05 (d, J = 4.9 Hz, 1H, H-1’); 5.93 (d, J = 2.2 Hz, 1H,  2’-OH); 5.22 (t, J 
= 5.5 Hz, 1H, 5’-OH); 4.61 − 4.57 (m, 1H, H-2’); 4.02 (dt, J = 3.1 and 8.6 Hz, 1H,  H-4’); 
3.79 − 3.43 (m, 4H, H-5’ and H-6’); 2.70 − 2.60 (m, 1H, H-3’); 13C-NMR (75 MHz, 
(CD3)2SO – d6): δ 156.75; 153.13; 149.43; 139.71; 119.80; 91.06; 83.63; 75.36; 62.20; 48.21; 
42.18. 
 
2.2. Synthesis of 9-(3-C-aminomethyl-3-deoxy-β-D-ribofuranosyl)adenine (3) 
To a solution of 2 (192.50 mg; 0.63 mmol) in dry THF (9 mL) triphenylphosphine 
(347 mg; 1.32 mmol) was added. To increase the solubility of 2 an additional amount of fry 
pyridine (4 mL) was added and after stirring for 8h at rt all starting material was converted. 
 5
Subsequently, H2O (0.5 mL) was added and the reaction was stirred for 16h. The solvents 
were evaporated and the crude amine 3 was used without further purification. 
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2.3. Synthesis of SC-23 
  A mixture of 3-(4-methoxyphenyl)propanoic acid (137.68 mg; 0.76 mmol) and 
HCTU (393.60 mg; 0.95 mmol) in dry DMF (5 mL) containing dipea (330 µL; 1.89 mmol) 
was stirred for 60 min at rt under N2-atmosphere. After that time crude 3, as obtained in 2.2 
and dissolved in dry DMF (8 mL), was added. TLC (DCM/0.7 N NH3 in MeOH 3:1) showed 
that the reaction was completed after 18h. Purification by column chromatography (DCM/0.7 
N NH3 in MeOH 9:1) afforded SC-23 (47.56 mg; 0.11 mmol; 17 %), which was further 
purified upon precipitation from a mixture of MeOH and diethyl ether to afford white solid 
material.  
1H-NMR (300 MHz, C5D5N – d5): δ 8.99 (s, 1H, H-8); 8.86 (br.s, 1H, -CO-NH); 8.66 
(s, 1H, H-2); 8.28 (s, 2H, -NH2); 7.70 (br.s, 1H, 2’-OH); 7.18 (d, J = 8.8 Hz, 2H,  arom. H); 
6.83 (d, J = 8.7 Hz, 2H,  arom. H); 6.69 (s, 1H, H-1’); 5.01 (br.s, 2H, H-2’ and 5’-OH); 4.61 
(d, J = 9.4 Hz, 1H, H-4’); 4.37 (dd, J = 2.3 and 12.2 Hz, 1H, H-5’); 4.22 − 4.02 (m, 2H, H-5’ 
and H-6’); 3.76 (dt, J = 5.3 and 13.4 Hz, 1H, H-6’); 3.60 (s, 3H, -OCH3); 3.27 (sep, J = 4.68 
Hz, 1H , H-3’); 3.07 (t, J = 7.4 Hz, 2H, -CH2-CO-NH-); 2.67 (t, J = 7.4 Hz, 2H, -Ph-CH2-); 
13C-NMR (75 MHz, C5D5N − d5): δ 173.90; 158.85; 157.81; 153.75; 139.80. 134.07; 130.08; 
121.39; 114.56; 92.47; 84.89; 77.35; 62.41; 55.41; 43.70; 38.95; 36.58; 31.59; HRMS (ESI-
MS): m/z: calcd: 443.2037 [M+1]; found = 443.2025 [M+1]. 
 
 
3. General procedure for the synthesis of amides SC-1, SC-2 and SC-3 
To a mixture of 3-(4-methoxyphenyl)propanoic acid (1.0 g; 5.55 mmol) and EDC (1.6 
g; 8.33 mmol) in dry THF (20 mL) were added 2.5 mL of TEA and 5 mL of a 2 M solution of 
the appropriate amine in THF. After stirring for 16h at rt, EtOAc (50 mL) was added and the 
organic phase was washed successively with an aqueous HCl solution (1 N; 50 mL; 2x), a 
saturated NaHCO3  solution (50 mL; 2x) and brine (50 mL). The organic phase was dried over 
Na2SO4 and evaporated. The residue could be purified by crystallization. 
 
3.1. 3-(4-methoxyphenyl)-N-methylpropanamide (SC-1) 
The title compound was crystallized from a mixture of isopropyl ether and heptanes to 
afford a first crop of colorless crystal needles (0.132 g; 0.68 mmol; 12 %). 
1H-NMR (300 MHz, (CD3)2CO – d6): δ 7.12 (d, J = 8.8 Hz, 2H, arom. H) ; 6.92 (br.s, 1H, -
CO-NH-); 6.81 (d, J = 8.5 Hz, 2H, arom. H); 3.75 (s, 3H, -OCH3); 2.82 (t, J = 8.2 Hz, 2H, -
CH2-CO-NH-); 2.66 (d, J = 4.7 Hz, 3H, -CO-NH-CH3); 2.38 (t, J = 7.8 Hz, 2H, -Ph-CH2-); 
13C-NMR (75 MHz, (CD3)2CO – d6): δ 171.95; 158.32; 133.81; 129.40; 113.85; 54.74; 38.06; 
30.81; 25.33; HRMS (ESI-MS): m/z: calcd: 194.1176 [M+1]; found 194.1173 [M+1]. 
 
3.2. N-cyclopentyl-3-(4-methoxyphenyl)propanamide (SC-2) 
The title compound was crystallized from isopropyl ether to afford a first crop of 
colorless crystal needles (0.418 g; 1.69 mmol; 30 %).  
1H-NMR (300 MHz, (CD3)2CO – d6): δ 7.11 (d, J = 8.8 Hz, 2H, arom. H); 6.91 (br.s, 
1H, -CO-NH-); 6.81 (d, J = 8.8 Hz, 2H, arom. H); 4.12 (sxt, J = 6.8 Hz, 1H, cyclopentyl-H); 
3.74 (s, 3H, -OCH3); 2.82 (t, J = 8.2 Hz, 2H, -CH2-CO-NH-); 2.35 (t, J = 7.8 Hz, 2H, -Ph-
CH2-); 1.90 − 1.76 (m, 2H, cyclopentyl-H); 1.68 – 1.46 (m, 4H, cyclopentyl-H); 1.43 – 1.28 
(m, 2H, cyclopentyl-H); 13C-NMR (75 MHz, (CD3)2CO – d6): δ 171.01; 158.32; 133.81; 
129.43; 113.82; 54.75; 50.89; 38.21; 32.74; 30.93; 23.67; HRMS (ESI-MS): m/z: calcd: 
248.1645 [M+1]; found 248.1632 [M+1].  
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3.2. N-benzyl-3-(4-methoxyphenyl)propanamide (SC-3) 
The title compound was crystallized from isopropyl ether to afford a first crop of 
colorless crystal needles (0.643 g; 2.39 mmol; 43 %).  
1H-NMR (300 MHz, (CD3)2CO − d6): δ 7.42 (br.s, 1H, -CO-NH-); 7.30 − 7.10 (m, 7H, 
benz. H and arom. H); 6.82 (d, J = 8.8 Hz, 2H, arom. H); 4.36 (d, J = 6.2 Hz, 2H, -CO-NH-
CH2-Ph); 3.76 (s, 3H, -OCH3); 2.87 (t, J = 7.6 Hz, 2H, -CH2-CO-NH-); 2.49 (t, J = 7.6 Hz, 
2H, -Ph-CH2-); 13C-NMR (75 MHz, (CD3)2CO – d6): δ 171.50; 158.37; 140.00; 133.64; 
129.54; 128.42; 127.59; 126.90; 113.868; 54.76; 42.69; 38.14; 30.84; HRMS (ESI-MS): m/z: 
calcd: 270.1489 [M+1]; found 270.1502 [M+1]. 
 
 
4. Synthesis of 3-deoxy-3-(3-(4-methoxyphenyl)propionamido)-1-O-methyl-D-
ribofuranose (SC-20) 
 
4.1. Synthesis of 2-O-acetyl-3-azido-3-deoxy-1-O-methyl-5-O-toluoyl-D-ribofuranose (5) and 
3-azido-3-deoxy-1-O-methyl-5-O-toluoyl-D-ribofuranose (6) 
 To a round-bottom flask supplied with flame-dried molecular sieves and kept under 
N2-atmosphere, was added a solution of 4 (502.85 mg; 1.33 mmol) in dry DCM (15 mL). The 
solution was cooled in an ice-bath and SnCl4 (320 µL; 2.66 mmol) was added. After stirring 
for 15 min, dry MeOH (175 µL; 4.26 mmol) was dripped in the reaction mixture. After 
stirring for 1h at 0 °C the reaction mixture was allowed to come to rt and stirred for another 
3h. After that time TLC (hexane/EtOAc 3:1) showed the disappearance of the starting 
material and the formation of two new products. The reaction mixture was diluted with DCM 
(150 mL), washed with a saturated NaHCO3 solution (150 mL, 2x) and the aqueous layer was 
extracted with EtOAc (100 mL). The combined organic layers were then washed with brine 
(150 mL), dried over Na2SO4, and evaporated. Compounds 5 and 6 were obtained as light 
yellow oils (respectively 39.4 mg; 8 % and 212 mg; 52 %) after purification with column 
chromatography (hexane/EtOAc 9:1 → 3:1). 
5:  1H-NMR (300 MHz, (CD3)2CO – d6): δ 7.98 (d, J = 8.3 Hz, 2H, arom. H), 7.34 (d, 
J = 8.0 Hz, 2H, arom. H); 5.27 (d, J = 4.79 Hz, 1H, H-2); 4.93 (s, 1H, H-1); 4.58 (dd, J = 3.8 
and 12.13 Hz, 1H, H-5); 4.47 − 4.38 (m, 2H, H-5 and H-3); 4.31 (ddd, J = 3.83 and 4.15 and 
7.98 Hz, 1H, H-4); 3.30 (s, 3H, -OCH3); 2.42 (s, 3H, -CO-CH3); 2.13 (s, 3H, CH3-Ph-); 13C-
NMR (75 MHz, (CD3)2CO – d6): δ 169.49; 165.87; 144.16; 129.78; 129.37; 127.54; 106.33; 
79.22; 76.40; 64.24; 61.04; 54.52; 20.90; 19.88.  
6: 1H-NMR (300 MHz, (CD3)2CO – d6): δ 7.93 (d, J = 8.3 Hz, 2H, arom. H); 7.33 (d, 
J = 8.0 Hz, 2H, arom. H); 4.93 (d, J = 4.17 Hz, 1H, H-1); 4.54 − 4.36 (m, 3H, H-2 and H-4 
and 2-OH); 4.22 (dd, J = 4.16 and 8.33 Hz, 1H, H-5); 4.13 (dd, J = 4.16 and 8.33 Hz, 1H, H-
5); 3.96 (d, J = 9.3 Hz, 1H, H-3); 3.40 (s, 3H, -OCH3); 2.41 (s, 3H, CH3-Ph-); 13C-NMR (75 
MHz, (CD3)2CO – d6): δ 165.83; 144.16; 129.70; 129.44; 127.51; 102.81; 79.43; 73.34; 
64.53; 61.47; 54.73; 20.91. 
 
4.2. Synthesis of 7.1 and 7.2, the two anomers of 3-azido-3-deoxy-1-O-methyl-D-ribofuranose 
Compounds 5 (39.4 mg; 0.11 mmol) and 6 (212 mg; 0.69 mmol) were separately 
treated with a methanolic solution of NH3 (7 N, respectively 18 and 25 mL) at rt. After 43h 
TLC (hexane/EtAOc 3:1) showed that both reactions were completed. After removal of the 
volatiles by evaporation, both residues were purified by column chromatography 
(hexane/acetone 7:3 for 7.1 and hexane/acetone 13:7 for 7.2).  
7.1: 1H-NMR (300 MHz, (CD3)2CO – d6): δ 4.80 (br.s, 1H, -OH); 4.78 (s, 1H, H-1); 
4.20 (br.s, 1H, H-2); 4.11 (dt, J = 3.8 and 8.9 Hz, 1H, H-4); 3.86 − 3.76 (m, 2H, -OH and H-
 7
3); 3.65 (br.s, 2H, H-5); 3.30 (s, 3H, -OCH3); 13C-NMR (75 MHz, (CD3)2CO – d6): 108.71; 
81.24; 76.13; 63.29; 62.36; 54.33. 
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7.2: 1H-NMR (300 MHz, (CD3)2CO – d6): δ 4.84 (d, J = 4.1 Hz, 1H, H-1); 4.33 − 4.23 
(m, 1H, H-2); 3.93 (m, 3H, -OH and H-3 and H-4 of H-5A); 3.79 (d, J = 9.77 Hz, 1H, -OH); 
3.64 (dd, J = 3.6 and 5.5 Hz, 2H, H-5B and H-5B of H-5B and H-4); 3.37 (s, 3H, -OCH3); 
13C-NMR (75 MHz, (CD3)2CO – d6):102.71; 82.44;73.39; 62.40; 61.46; 54.51. 
 
4.3. Synthesis of 3-amino-3-deoxy-1-O-methyl-D-ribofuranose (8) 
To a solution of 7.2 (121.70 mg; 0.64 mmol) in dry pyridine (6 mL) 
triphenylphosphine (363.80 mg; 1.39 mmol) was added and the mixture was stirred for 8h at 
rt under N2-atmosphere. After that time the starting material was completely consumed (TLC: 
DCM/0.7 N NH3 in MeOH 9:1). Subsequently, H2O (0.5 mL) was added and after stirring for 
16h, the solvents were removed and the residue was used in the next step without further 
purification. 
 
4.4. Synthesis of 3-deoxy-3-(3-(4-methoxyphenyl)propionamido)-1-O-methyl-D-ribofuranose 
(SC-20) 
After incubating a mixture of 3-(4-methoxyphenyl)propanoic acid (145.39 mg; 0.81 
mmol), HCTU (397.54 mg; 0.96 mmol) and dipea (330 µL; 1.89 mmol) in dry DMF (5 mL) 
for 60 min at rt under N2-atmosphere, a solution of the residue obtained in 4.3 in dry DMF (4 
mL) was added. After stirring for 23h TLC (DCM/0.7 N NH3 in MeOH 3:1) demonstrated 
complete reaction. Following purification by column chromatography (DCM/0.7 N NH3 in 
MeOH 19:1) and crystallization of a contaminant from a mixture of EtOAc and isopropyl 
ether, a second chromatographic purification (hexane/acetone 1:1) afforded a residue that was 
dissolved in EtOAc. This solution was washed successively with a HCl solution (0.5 N, 15 
mL, 3x) and brine (50 mL), dried over Na2SO4, and evaporated to afford pure SC-20 as a 
colorless viscous oil (67.40 mg; 0.21 mmol; 33 %).  
1H-NMR (300 MHz, (CD3)2CO – d6): δ 7.14 (d, J = 8.8 Hz, 2H, arom. H); 6.90 (br.s, 
1H, -CO-NH-); 6.83 (d, J = 8.8 Hz, 2H, arom. H); 4.86 (d, J = 4.1 Hz, 1H, H-1); 4.22 − 4.14 
(m, 2H, H-2 and H-3); 4.05 (dd, J = 5.3 and 7.0 Hz, 1H, 5-OH); 3.85 (d, J = 7.0 Hz, 1H, 2-
OH); 3.77 − 3.72 (m, 4H, -OCH3 and H-4); 3.64 − 3.51 (m, 2H, H-5); 3.35 (s, 3H, -OCH3); 
2.84 (dd, J = 6.4 and 8.8 Hz, 2H, -CH2-CO-); 2.51 (dd, J = 6.8 and 8.6 Hz, 2H, -Ph-CH2-); 
13C-NMR (75 MHz, (CD3)2CO – d6): δ 173.22; 159.06; 134.10; 130.13; 114.56; 103.81; 
85.13; 71.58; 63.36; 55.43; 55.18; 51.93; 38.62; 31.45; HRMS (ESI-MS): m/z: calcd: 
326.1604 [M+1]; found 326.1598 [M+1]. 
 
5. Elemental Analysis 
 
Calculated Found 
  C H N C H N 
LMC 23 49.99 5.99 24.99 50.22 6.13 24.33 
LMC-20 61.58 7.27 15.96 61.02 7.38 15.80 
IK-1 56.42 6.98 20.78 56.80 6.75 20.44 
LMC-21 56.07 5.65 19.62 56.00 5.83 19.29 
LMC-27 57.57 5.09 21.20 57.90 5.39 20.97 
LMC-28 56.33 5.20 19.71 56.33 5.29 19.62 
SC-23 57.00 5.92 18.99 57.32 5.90 18.71 
PVR-21 51.25 4.78 16.60 51.10 4.88 16.15 
LMC-29 53.77 4.75 26.40 53.67 4.89 26.08 
 8
LMC-30 50.49 5.98 27.71 50.69 6.08 27.41 
LMC-35 47.40 5.72 31.09 47.55 5.64 30.41 
SC-1 68.37 7.82 7.25 68.44 7.91 7.33 
SC-2 72.84 8.56 5.66 72.99 8.69 5.68 
SC-3 75.81 7.11 5.20 76.03 7.19 5.09 
SC-20 59.06 7.13 4.31 Not available 
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Supplementary Table 1: Lack of effect of various compounds on the constitutive 
bioluminescence of E. coli DH5αpBlueLux. Expressed as % (mean±standard deviation) of 
luminescence in control without compound. 
256 
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Compound Luminescence in E. coli DH5α 
pBluelux  
KM-03009 (40 µM) 97 ± 8 % 
LMC-21 (40 µM) 98 ± 4 % 
LMC-28 (40 µM) 101 ± 6 % 
MCPBA (40 µM) 96 ± 11 % 
Pyrogallol (40 µM) 95 ± 14 % 
SC-23 (160 µM) 103 ± 7 
SC-20 (40 µM) 102 ± 11 % 
 260 
261 
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Supplementary Table 2 : Relative number (expressed as %) metabolically active cells in 
biofilms, compared to untreated controls (mean±standard deviation). Data are based on 
resazurin viability staining. 
263 
264 
265 
 V. anguillarum V. campbellii V. cholerae V. harveyi V. vulnificus 
 LMG4411 LMG21363 NCTC8457 BB120 LMG16867 
Control 100 ± 23 100 ± 18 100 ± 12  100 ± 11 100 ± 19 
LMC-21  90 ± 11 99 ± 10 102 ± 14 104 ± 8 97 ± 8 
KM-03009 101 ± 14 104 ± 12 104 ± 16 104 ± 9 105 ± 13 
MCPBA  101 ± 26 93 ± 9 93 ± 22 103 ± 13 92 ± 22 
Pyrogallol 91 ± 23 96 ± 18 99 ± 18 106 ± 12  95 ± 18 
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Supplementary Table 3 : MIC (µg/ml) for chloramphenicol when used alone or in 
combination with QSI.  
269 
270 
 V. anguillarum V. campbellii V. cholerae V. harveyi V. vulnificus 
 LMG4411 LMG21363 NCTC8457 BB120 LMG16867 
Control 1 2 1 2 1 
LMC-21  1 2 1 2 1 
KM-03009 1 2 1 2 1 
MCPBA  1 2 1 2 1 
Pyrogallol 1 2 1 2 1 
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274 
275 
Supplementary Table 4 : MIC (µg/ml) for doxycycline when used alone or in combination 
with QSI.  
 V. anguillarum V. campbellii V. cholerae V. harveyi V. vulnificus 
 LMG4411 LMG21363 NCTC8457 BB120 LMG16867 
Control 64 64 32 64 8 
LMC-21  64 64 32 64 8 
KM-03009 64 64 32 64 8 
MCPBA  64 64 32 64 8 
Pyrogallol 64 64 32 64 8 
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